Literature DB >> 15728493

The Ig kappa 3' enhancer is activated by gradients of chromatin accessibility and protein association.

Daniel C McDevit1, Leslie Perkins, Michael L Atchison, Barbara S Nikolajczyk.   

Abstract

The Igkappa locus is recombined following initiation of a signaling cascade during the early pre-B stage of B cell development. The Ig kappa3' enhancer plays an important role in normal B cell development by regulating kappa locus activation. Quantitative analyses of kappa3' enhancer chromatin structure by restriction endonuclease accessibility and protein association by chromatin immunoprecipitation in a developmental series of primary murine B cells and murine B cell lines demonstrate that the enhancer is activated progressively through multiple steps as cells mature. Moderate kappa3' chromatin accessibility and low levels of protein association in pro-B cells are increased substantially as the cells progress from pro- to pre-B, then eventually mature B cell stages. Chromatin immunoprecipitation assays suggest transcriptional regulators of the kappa3' enhancer, specifically PU.1 and IFN regulatory factor-4, exploit enhanced accessibility by increasing association as cells mature. Characterization of histone acetylation patterns at the kappa3' enhancer and experimental inhibition of histone deacetylation suggest changes therein may determine changes in enzyme and transcription factor accessibility. This analysis demonstrates kappa activation is a multistep process initiated in early B cell precursors before Igmu recombination and finalized only after the pre-B cell stage.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15728493     DOI: 10.4049/jimmunol.174.5.2834

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  A developmentally controlled competitive STAT5-PU.1 DNA binding mechanism regulates activity of the Ig κ E3' enhancer.

Authors:  Suchita Hodawadekar; Kyoungsook Park; Michael A Farrar; Michael L Atchison
Journal:  J Immunol       Date:  2012-01-25       Impact factor: 5.422

2.  Epigenetic histone modifications do not control Igkappa locus contraction and intranuclear localization in cells with dual B cell-macrophage potential.

Authors:  Suchita Hodawadekar; Fang Wei; Duonan Yu; Andrei Thomas-Tikhonenko; Michael L Atchison
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

3.  Immunoglobulin kappa enhancers are differentially regulated at the level of chromatin structure.

Authors:  Barbara S Nikolajczyk; Sylvia H Sardi; Joseph R Tumang; Lisa M Ganley-Leal
Journal:  Mol Immunol       Date:  2007-03-26       Impact factor: 4.407

4.  Enhancers as regulators of antigen receptor loci three-dimensional chromatin structure.

Authors:  E Mauricio Barajas-Mora; Ann J Feeney
Journal:  Transcription       Date:  2019-12-12

5.  Dynamic protein associations define two phases of IL-1beta transcriptional activation.

Authors:  Yue Zhang; Simona Saccani; Hyunjin Shin; Barbara S Nikolajczyk
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

6.  B cells from periodontal disease patients express surface Toll-like receptor 4.

Authors:  Hyunjin Shin; Yue Zhang; Madhumita Jagannathan; Hatice Hasturk; Alpdogan Kantarci; Hongsheng Liu; Thomas E Van Dyke; Lisa M Ganley-Leal; Barbara S Nikolajczyk
Journal:  J Leukoc Biol       Date:  2008-12-31       Impact factor: 4.962

7.  Bright/ARID3A contributes to chromatin accessibility of the immunoglobulin heavy chain enhancer.

Authors:  Danjuan Lin; Gregory C Ippolito; Rui-Ting Zong; James Bryant; Janet Koslovsky; Philip Tucker
Journal:  Mol Cancer       Date:  2007-03-26       Impact factor: 27.401

8.  A novel pax5-binding regulatory element in the igκ locus.

Authors:  Rena Levin-Klein; Andrei Kirillov; Chaggai Rosenbluh; Howard Cedar; Yehudit Bergman
Journal:  Front Immunol       Date:  2014-05-23       Impact factor: 7.561

9.  miR290-5p/292-5p activate the immunoglobulin kappa locus in B cell development.

Authors:  Patty B Garcia; Amie Cai; Jamie G Bates; Hector Nolla; Mark S Schlissel
Journal:  PLoS One       Date:  2012-08-23       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.